A SINGLE CENTER, OPEN LABEL, SINGLE ARM STUDY TO INVESTIGATE THE REPEATED DOSE (FOR 10 DAYS) PHARMACOKINETICS AFTER ORAL ADMINISTRATION OF 200 MG PF-06651600 IN CHINESE HEALTHY ADULT PARTICIPANTS
Latest Information Update: 18 Feb 2021
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 18 Dec 2020 Status changed from recruiting to completed.
- 24 Nov 2020 New trial record